P-179: Impact of the inhibition of soluble epoxide hydrolase on cardiovascular consequences of chronic kidney disease

2015 ◽  
Vol 64 ◽  
pp. S83
Author(s):  
M. Hamzaoui ◽  
C. Roche ◽  
A. Lejeune ◽  
V. Brunel ◽  
V. Richard ◽  
...  
2016 ◽  
Vol 12 (5) ◽  
pp. 412
Author(s):  
M. Hamzaoui ◽  
C. Roche ◽  
A. Lejeune ◽  
V. Brunel ◽  
V. Richard ◽  
...  

2016 ◽  
Vol 8 (3) ◽  
pp. 233
Author(s):  
Mouad Hamzaoui ◽  
Clothilde Roche ◽  
Annie Lejeune ◽  
Valery Brunel ◽  
Vincent Richard ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Stefanos Roumeliotis ◽  
Athanasios Roumeliotis ◽  
Aikaterini Stamou ◽  
Stylianos Panagoutsos ◽  
Vangelis G. Manolopoulos ◽  
...  

Soluble epoxide hydrolase 2 (EPHX2) is an enzyme promoting increased cellular apoptosis through induction of oxidative stress (OS) and inflammation. The EPHX2 gene which encodes soluble EPHX2 might be implicated in the pathogenesis and development of OS and atherosclerosis. We aimed to assess the possible association between two functional polymorphisms of the EPHX2 gene (rs2741335 and rs11780592) with oxidized LDL (ox-LDL), carotid atherosclerosis, mortality, and cardiovascular (CV) disease in 118 patients with diabetic chronic kidney disease (CKD). At baseline, ox-LDL and carotid intima-media thickness (cIMT) were evaluated and all patients were followed for seven years with outcomes all-cause mortality and CV events. rs11780592 EPHX2 polymorphism was associated with ox-LDL, cIMT, albuminuria, and hypertension. Compared to AG and GG, AA homozygotes had higher values of albuminuria, ox-LDL, and cIMT ( p = 0.046 , p = 0.003 , and p = 0.038 , respectively). These associations remained significant, even after grouping for the G allele. After the follow-up period, 42/118 patients died (30/60 with AA genotype, 11/42 with AG genotype, and 1/12 with GG genotype) and 49/118 experienced a new CV event (fatal or nonfatal). The Kaplan-Meier analysis revealed that patients with the AA genotype exhibited a significantly higher mortality risk, compared to patients with AG and GG genotypes ( p = 0.006 ). This association became even stronger, when AG and GG genotypes were grouped (AA vs. AG/GG, p = 0.002 ). AA homozygotes were strongly associated with all-cause mortality in both univariate (hazard ratio HR = 2.74 , confidence interval CI = 1.40 – 5.35 , p = 0.003 ) and multivariate Cox regression analysis ( HR = 2.61 , CI = 1.32 – 5.17 , p = 0.006 ). In conclusion, our study demonstrated that genetic variations of EPHX2 gene were associated with increased circulating ox-LDL, increased cIMT, and all-cause mortality in diabetic CKD. Since EPHX2 regulates the cholesterol efflux and the oxidation of LDL in foam cells and macrophages, our study suggests that a genetic basis to endothelial dysfunction and OS might be present in diabetic CKD.


2019 ◽  
Vol 44 (6) ◽  
pp. 1493-1505 ◽  
Author(s):  
Věra Čertíková Chábová ◽  
Petr Kujal ◽  
Zdeňka Vaňourková ◽  
Petra Škaroupková ◽  
Janusz Sadowski ◽  
...  

Introduction: Previous studies in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX) have shown that besides pharmacological blockade of the renin-angiotensin system (RAS) also increasing kidney tissue epoxyeicosatrienoic acids (EET) levels by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for degradation of EETs, and endothelin type A (ETA) receptor blockade retards chronic kidney disease (CKD) progression. This prompted us to evaluate if this progression will be alleviated by the addition of sEH inhibitor and ETA receptor antagonist to the standard complex blockade of RAS (angiotensin-converting enzyme inhibitor plus angiotensin II type 1 receptor blocker) in rats with established CKD. Methods: The treatment regimens were initiated 6 weeks after 5/6 NX in TGR, and the follow-up period was 60 weeks. Results: The addition of sEH inhibition to RAS blockade improved survival rate, further reduced albuminuria and renal glomerular and kidney tubulointerstitial injury, and attenuated the decline in creatinine clearance – all this as compared with 5/6 NX TGR treated with RAS blockade alone. Addition of ETA receptor antagonist to the combined RAS and sEH blockade not only offered no additional renoprotection but, surprisingly, also abolished the beneficial effects of adding sEH inhibitor to the RAS blockade. Conclusion: These data indicate that pharmacological strategies that combine the blockade of RAS and sEH could be a novel tool to combat the progression of CKD. Any attempts to further extend this therapeutic regimen should be made with extreme caution.


Metabolites ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 169
Author(s):  
Kyoung Hee Han ◽  
Bora Kim ◽  
Sang Chun Ji ◽  
Hee Gyung Kang ◽  
Hae Il Cheong ◽  
...  

While a complex network of cellular and molecular events is known to be involved in the pathophysiological mechanism of chronic kidney disease (CKD), the divergence point between reversal and progression and the event that triggers CKD progression are still unknown. To understand the different mechanisms between reversible and irreversible kidney disease and to search for urinary biomarkers that can predict prognosis, a metabolomic analysis was applied to compare acute and chronic experimental glomerulonephritis (GN) models. Four metabolites, namely, epoxyoctadecenoic acid (EpOME), epoxyeicosatetraenoic acid (EpETE), α-linolenic acid (ALA), and hydroxyretinoic acid, were identified as predictive markers after comparing the chronic nephritis model with acute nephritis and control groups (false discovery rate adjusted p-value (q-value) < 0.05). Renal mRNA expression of cytochrome P450 and epoxide hydrolase was also identified as being involved in the production of epoxide metabolites from these polyunsaturated fatty acids (p < 0.05). These results suggested that the progression of chronic kidney disease is associated with abnormally activated epoxide hydrolase, leading to an increase in EpOME and EpETE as pro-inflammatory eicosanoids.


Theranostics ◽  
2020 ◽  
Vol 10 (17) ◽  
pp. 7857-7871
Author(s):  
Jihong Lin ◽  
Jiong Hu ◽  
Andrea Schlotterer ◽  
Jing Wang ◽  
Matthias Kolibabka ◽  
...  

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i370-i370
Author(s):  
Vera Certikova Chabova ◽  
Petr Kujal ◽  
Petra Skaroupkova ◽  
Zdenka Vanourkova ◽  
Libor Kopkan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document